CASTELLI R, GIDARO A, LAMBERTENGHI DELILIERS G.
“ELTROMBOPAG REDUCES BLEEDING COMPLICATIONS AND THE NEED OF PLATELET TRANSFUSIONS IN CIRRHOTIC THROMBOCYTOPENIC PATIENTS SUBJECTED TO INVASIVE PROCEDURES”
Blood Coagul Fibrinolysis. 2021;32(2):163-6
CASTELLI R, GIDARO A, LAMBERTENGHI DELILIERS G, BERGAMASCHINI L.
“BENDAMUSTINE IN ASSOCIATION WITH RITUXIMAB FOR FIRST-LINE TREATMENT OF DIFFUSE LARGE B-CELL LYMPHOMA IN FRAIL PATIENTS INELIGIBLE FOR R-CHOP/R-CHOP-LIKE TREATMENTS”
Anti-Cancer Drugs. 2021;32(3):323-9
MORA B, GUGLIELMELLI P, RUMI E, ET AL.
“IMPACT OF BONE MARROW FIBROSIS GRADE IN POST-POLYCYTHEMIA VERA AND POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS. A STUDY OF THE MYSEC GROUP”
Am J Hematol. 2020 Jan;95(1):E1-E3
MERLI M, BIANCHI B, BERTU’ L, ET AL.
“VALIDATION AND FURTHER POTENTIALITIES OF THE NOVEL AWM SCORE FOR PROGRESSION RISK STRATIFICATION IN PATIENTS WITH ASYMPTOMATIC WALDENSTROEM MACROGLOBULINEMIA”
Leuk Lymphoma. 2020 Apr;61(4):987-989
MERLI M, DEFRANCESCO I, VISCO C, ET AL.
“DIRECT-ACTING ANTIVIRALS IN RELAPSED OR REFRACTORY HEPATITIS C VIRUS-ASSOCIATED DIFFUSE LARGE B-CELL LYMPHOMA”
Leuk Lymphoma. 2020 Sep;61(9):2122-2128
MERLI M, AGENO W, SESSA F, ET AL.
“RECURRENCE OF IMMUNE THROMBOCYTOPENIA AT THE TIME OF SARS-COV-2 INFECTION”
Ann Hematol. 2020 Aug;99(8):1951-1952
MERLI M, LUMINARI S, FARINA L, ET AL.
“STEM CELL MOBILIZATION AFTER BENDAMUSTINE IN INDOLENT LYMPHOMAS: A MULTICENTER STUDY ON BEHALF OF THE FONDAZIONE ITALIANA LINFOMI”
Bone Marrow Transplant. 2020 Dec;55(12):2350-2353
DEBUREAUX PE, CASSINAT B, SORET-DULPHY J, ET AL.
“MOLECULAR PROFILING AND RISK CLASSIFICATION OF PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS AND SPLANCHNIC VEIN THROMBOSES”
Blood Adv. 2020 Aug 11;4(15):3708-3715
TACCHETTI P, PANTANI F, PATRIARCA MT, ET AL.
“BORTEZOMIB, THALIDOMIDE, AND DEXAMETHASONE FOLLOWED BY DOUBLE AUTOLOGOUS HAEMATOPOIETIC STEM-CELL TRANSPLANTATION FOR NEWLY DIAGNOSED MULTIPLE MYELOMA (GIMEMA-MMY-3006) LONG-TERM FOLLOW-UP ANALYSIS FOR A RANDOMISED PHASE 3, OPEN-LABEL STUDY”
Lancet Haematol. 2020;7(12):e861-e873
CASTELLI R, LAMBERTENGHI DELILIERS G, GIDARO A, ET AL.
“COMPLEMENT ACTIVATION IN PATIENTS WITH IMMUNE THROMBOCYTOPENIC PURPURA ACCORDING TO PHASES OF DISEASE COURSE”
Clin Exp Immunol. 2020;201(3):258-65
CASTELLI R, GIDARO A, LAMBERTENGHI DELILIERS G.
“RISK OF THROMBOSIS IN ELDERLY IMMUNE PRIMARY THROMBOCYTOPENIC PATIENTS TREATED WITH THROMBOPOIETIN RECEPTORS AGONISTS”
J Thromb Thrombolysis. 2020;50(4):903-7
CASTELLI R, BERGAMASCHINI L, TEATINI T, ET AL.
“DOES OUTCONE/SURVIVAL OF PATIENTS WITH MYELODYSPLASTIC SYUNDROMES SHOULD BE PREDICTED BY REDUCED LEVELS OF ADAMTS-13? RESULTS FROM A PILOT STUDY”
Clin Lymphoma, Myeloma Leuk. 2020:20(8):461-7
CASTELLI R, SCHIAVON R, PRETI C, LAMBERTENGHI DELILIERS G.
“IBRUTINIB RELATED BLEEDING COMPLICATIONS IN ELDERLY PATIENTS WITH B CELLS MALIGNANCIES”
J Thromb Thrombolysis. 2019;48(4):694-6
CASTELLI R, GALLIPOLI P, SCHIAVON R, TEATINI T, LAMBERTENGHI DELILIERS G, BERGAMASCHINI L.
“INCREASED RISK OF HEPARIN INDUCED THROMBOCYTOPENIA AND THROMBOSIS IN PATIENTS WITH ESSENTIAL THROMBOCYTHEMIA CARRYING THE HOMOZYGOUS JAK2 V617F MUTATION”
J Thromb Thrombolysis. 2019;47(1):155-6
BARRACO D, MAFFIOLI M, PASSAMONTI F.
“STANDARD CARE AND INVESTIGATIONAL DRUGS IN THE TREATMENT OF MYELOFIBROSIS”
Drugs in Context. 2019;8:212603
MORA B & PASSAMONTI F.
“DEVELOPMENT IN DIAGNOSIS AND TREATMENT OF ESSENTIAL THROMBOCYTEMIA”
Expert Rev Hematol. 2019;12(3):159-71
MERLI M, FRIGENI M, ALRIC L, ET AL.
“DIRECT-ACTING ANTIVIRALS IN HEPATITIS C VIRUS-ASSOCIATED DIFFUSE LARGE B-CELL LYMPHOMAS”
The Oncologist. 2019;24:e720-9
MORA B, RUMI E, GUGLIELMELLI P, ET AL.
“SECOND PRIMARY MALIGNANCIES IN POSTPOLYCYTHEMIA VERA AND POSTESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS: A STUDY ON 2233 PATIENTS”
Cancer Med. 2019;8:4089-92
ELLI EM, IURLO A, AROLDI A , ET AL.
“DEFERASIROX IN THE MANAGEMENT OF IRON-OVERLOAD IN PATIENTS WITH MYELOFIBROSIS: A MULTICENTRE STUDY FROM THE RETE EMATOLOGICA LOMBARDA (IRON-M STUDY)”
Br J Haematol. 2019;186:e117-e126
MAFFIOLI M, ORLANDI E , PASSAMONTI F.
“CHRONIC MYELOPROLIFERATIVE NEOPLASMS IN THE ELDERLY”
Eur J Int Med. 2018;58:33-42
MORA B, GIORGINO T, GUGLIELMELLI P, ET AL.
“PHENOTYPE VARIABILITY OF PATIENTS WITH POST POLYCYTHEMIA VERA AND POST ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS IS ASSOCIATED WITH THE TIME TO PROGRESSION FROM POLYCYTHEMIA VERA AND ESSENTIAL THROMBOCYTHEMIA”
Leuk Res. 2018;69:100-2
MORA B, GIORGINO T, GUGLIELMELLI P, ET AL.
“VALUE OF CYTOGENETIC ABNORMALITIES IN POST-POLYCYTHEMIA VERA AND POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS: A STUDY OF THE MYSEC PROJECT”
Haematologica. 2018;103:e392
TEFFERI A, MUDIREDDY M, MANNELLI F, ET AL.
“BLAST PHASE MYELOPROLIFERATIVE NEOPLASM: MAYO-AGIMM STUDY OF 410 PATIENTS FROM TWO SEPARATE COHORTS”
Leukemia. 2018;32(5):1200-10
PASSAMONTI F, MAFFIOLI M.
“THE ROLE OF JAK2 INHIBITORS IN MPNs 7 YEARS AFTER APPROVAL”
Blood. 2018;131(22):2426-35
MERLI M, FRIGENI M, ALRIC L, ET AL.
“DIRECT ACTING ANTIVIRALS IN HEPATITIS C VIRUS-ASSOCIATED DIFFUSE LARGE B-CELL LYMPHOMAS”
The Oncologist. 2018;23(10):1-10
BARRACO D, MORA B, GUGLIELMELLI P, ET AL.
“GENDER EFFECT ON PHENOTYPE AND GENOTYPE IN PATIENTS WITH POST-POLYCYTHEMIA VERA AND POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS: RESULTS OF THE MYSEC PROJECT”
Blood Cancer J. 2018;8(10):89
CASTELLI R, GALLIPOLI P, SCHIAVON R, TEATINI T, LAMBERTENGHI DELILIERS G, BERGAMASCHINI L.
“HIGH PREVALENCE OF HEPARIN INDUCED THROMBOCYTOPENIA WITH THROMBOSIS AMONG PATIENTS WITH ESSENTIAL THROMBOCYTEMIA CARRYING V617F MUTATION”
J Thromb Thrombolysis. 2018;45(1):106-113
CASTELLI R, SCHIAVON R, ROSSI V, ET AL.
“MANAGEMENT OF ANEMIA IN LOW-RISK MYELODYSPLASTIC SYUNDROMES TREATED WITH ERYTHROPOIESIS-STIMULATING AGENTS NEWER AND OLDER AGENTS”
Med Oncol. 2018:35(5):76
CASTELLI R, SCHIAVON R, LAMBERTENGHI DELILIERS G.
“THE IMPACT OF ANAEMIA, TRANSFUSIONE DEPENDENCY, COMORBIDITIES AND POLYPHARMACY IN ELDERLY PATIENTS WITH LOW.-RISK MYELODYSPLASTIC SYNDROMES”
J Med Oncol. 2018;35(3):33
CASTELLI R, BERGAMASCHINI L, LAMBERTENGHI DELILIERS G.
“FIRST-LINE TREATMENT WITH BENDAMUSTINE AND RITUXIMAB, IN PATIENTS WITH INTERMEDIATE-/HIGH-RISK SPLENIC MARGINAL ZONE LYMPHOMAS”
J Med Oncol. 2018;35(2):15
PASSAMONTI F, MAFFIOLI M, MORA B.
“THERAPY OF POLYCYTHEMIA VERA: IT IS TIME TO CHANGE?”
Oncotarget. 2017;8(61):102759-60
CASTELLI R, BERGAMASCHINI L, SCHIAVON R, LAMBERTENGHI DELILIERS G.
“PERSONALIZED TREATMENT STRATEGIES FOR ELDERLY PATIENTS WITH MYELODYSPLASTIC SYNDROMES”
J Expert Rev Hematol. 2017;10(12):1077-86
MAFFIOLI M, MORA B, PASSAMONTI F.
“POLYCYTHEMIA VERA: FROM NEW, MODIFIED DIAGNOSTIC CRITERIA TO NEW THERAPEUTIC APPROACHES”
J Clin Adv Hematol Oncol. 2017;15(9):700-7
ANNALORO C, AIRAGHI L, MOMETTO G, MAIRA D.
“SINDROME METABOLICA”
Ematologia Oncologica.it 2017, Anno 4, N.1.
KROEGER N, IACOBELLI S, NIEDERWIESER D, PLATZBECKER U, UDDIN R, HUEBEL K, ET AL.
“DOSE-REDUCED VERSUS STANDARD CONDITIONING FOLLOWED BY ALLOGENEIC STEM-CELL TRANSPLANTATION FOR PATIENTS WITH MYELODYSPLASTIC SYNDROME: A PROSPECTIVE RANDOMIZED PHASE III STUDY OF THE EBMT (RICMAC-TRIAL)”
J Clin Oncol. 2017;35(19):2157-64
PASSAMONTI F, GIORGINO T, MORA B, GUGLIELMELLI P, RUMI E, ET AL.
“A CLINICAL-MOLECULAR PROGNOSTIC MODEL TO PREDICT SURVIVAL IN PATIENTS WITH POST POLYCYTHEMIA VERA AND POST ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS”
Leukemia. 2017;31(12):2726-31
PASSAMONTI F, MORA B, GIORGINO T, GUGLIELMELLI P, CAZZOLA M, MAFFIOLI M, ET AL.
“DRIVER MUTATIONS’ EFFECT IN SECONDARY MYELOFIBROSIS: AN INTERNATIONAL MULTICENTER STUDY BASED ON 781 PATIENTS”
Leukemia. 2017;31(4):970-3
CASTELLI R, SCIARA S, LAMBERTENGHI DELILIERS G, PANTALEO G.
“BIOSIMILAR EPOETIN ALFA INCREASES HAEMOGLIBIN LEVELS AND BRINGS COGNITIVE AND SOCIO-RELATIONAL BENEFITS TO ELDERLY TRANSFUSION-DEPENDENT MULTIPLE MYELOMA PATIENTS: RSULTS FROM A PILOT STUDY”
Ann Hematol. 2017;96(5):779-86
CASTELLI R, FERRARIS L, PANTALEO G, LAMBERTENGHI DELILIERS G, CICARDI M.
“HIGH RATE OF HEPATITIS B VIRAL BREAKTHROUGH IN ELDERLY NON-HODGKIN LYMPHOMAS PATIENTS TREATED WITH RITUXIMAB BASED CHEMOTHERAPY”
Dige Liver Dis. 2016;48:1394–7
CASTELLI R, GIDARO A, LAMBERTENGHI DELILIERS G.
“BENDAMUSTINE AND RITUXIMAB, AS FIRST LINE TREATMENT, IN INTERMEDIATE, HIGH RISK SPLENIC MARGINAL ZONE LYMPHOMAS OF ELDERLY PATIENTS”
Mediterr J Hematol Infect Dis. 2016;8:1-5
GIDARO A, LAMBERTENGHI DELILIERS G, GALLIPOLI P, ARQUATI M, WU MA, CASTELLI R.
“LABORATORY AND CLINICAL RISK ASSESSMENT TO THREAT MYELODYSPLASTIC SYNDROMES”
Clin Chem Lab Med. 2016;54:1411-26
LAMBERTENGHI DELILIERS G, ANNALORO C.
“ALTERAZIONI QUANTITATIVE E QUALITATIVE DEI LEUCOCITI”
In: Manuale di Ematologia-Edizioni Minerva Medica (II ed.) Capitolo 7°, pp 77-89, 2015
CASTELLI R, PANTALEO G, GALLIPOLI P, GIDARO A, ARQUATI M, WU MA, LAMBERTENGHI DELILIERS G.
“SALVAGE THERAPY WITH BORTEZOMIB AND DEXAMETHASONE IN ELDERLY PATIENTS WITH RELAPSED/REFRACTORY MYLTIPLE MYELOMA”
Anti-Cancer Drugs. 2015;26:1078–82
CASTELLI R, DELILIERS GL, COLOMBO R, MOREO G, GALLIPOLI P, PANTALEO G.
”BIOSIMILAR EPOETIN IN ELDERLY PATIENTS WITH LOW-RISK MYELODYSPLASTIC SYNDROMES IMPROVES ANEMIA, QUALITY OF LIFE, AND BRAIN FUNCTION”
